BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34098552)

  • 1. Persistence and Severity of Cutaneous Manifestations in IgA Vasculitis Is Associated with Development of IgA Vasculitis Nephritis in Children.
    Sestan M; Srsen S; Kifer N; Sapina M; Batnozic Varga M; Ovuka A; Held M; Kozmar A; Frkovic M; Laskarin G; Gagro A; Jelusic M
    Dermatology; 2022; 238(2):340-346. PubMed ID: 34098552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal involvement and its association with the risk for nephritis in IgA vasculitis.
    Sestan M; Kifer N; Frkovic M; Sapina M; Srsen S; Batnozic Varga M; Ovuka A; Held M; Gudelj Gracanin A; Kozmar A; Bulimbasic S; Coric M; Laskarin G; Gagro A; Jelusic M
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211024828. PubMed ID: 34262620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and risk factors for kidney involvement in children with immunoglobulin A vasculitis.
    Chatpaitoon B; Rianthavorn P; Chanakul A; Khaosut P
    Pediatr Int; 2024; 66(1):e15781. PubMed ID: 38863300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: Multicenter international study.
    Sestan M; Kifer N; Sozeri B; Demir F; Ulu K; Silva CA; Campos RT; Batu ED; Koker O; Sapina M; Srsen S; Held M; Gagro A; Fonseca AR; Rodrigues M; Rigante D; Filocamo G; Baldo F; Heshin-Bekenstein M; Giani T; Kataja J; Frkovic M; Ruperto N; Ozen S; Jelusic M;
    Semin Arthritis Rheum; 2023 Aug; 61():152209. PubMed ID: 37126983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geospatial clustering of childhood IgA vasculitis and IgA vasculitis-associated nephritis.
    Sapina M; Frkovic M; Sestan M; Srsen S; Ovuka A; Batnozic Varga M; Kramaric K; Brdaric D; Milas K; Gagro A; Jelusic M
    Ann Rheum Dis; 2021 May; 80(5):610-616. PubMed ID: 33208346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Urinary IgA in Paediatric IgA Vasculitis Nephritis.
    Marro J; Chetwynd AJ; Edwards S; Wright RD; Oni L
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of children with IgA vasculitis with nephritis treated with steroids: a matched controlled study.
    Mary AL; Clave S; Rousset-Rouviere C; Berard E; Boyer O; Decramer S; Fila M; Guigonis V; Cloarec S; Harambat J; Hogan J; Lahoche A; Roussey-Kesler G; Zaloszyc A; Ulinski T; Parmentier C; Delbet JD
    Pediatr Nephrol; 2023 Oct; 38(10):3317-3326. PubMed ID: 37154959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis.
    Demir S; Kaplan O; Celebier M; Sag E; Bilginer Y; Lay I; Ozen S
    Semin Arthritis Rheum; 2020 Dec; 50(6):1238-1244. PubMed ID: 33065418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgA vasculitis.
    Pillebout E; Sunderkötter C
    Semin Immunopathol; 2021 Oct; 43(5):729-738. PubMed ID: 34170395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Pediatric Vasculitis Activity Score with immunoglobulin A vasculitis with nephritis.
    Avcı B; Kurt T; Aydın F; Çelikel E; Tekin ZE; Sezer M; Tekgöz N; Karagöl C; Coşkun S; Kaplan MM; Bayrakçı US; Acar B
    Pediatr Nephrol; 2023 Mar; 38(3):763-770. PubMed ID: 35895124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid metabolism contribute to the pathogenesis of IgA Vasculitis.
    Liu Y; Wen M; He Q; Dang X; Feng S; Liu T; Ding X; Li X; He X
    Diagn Pathol; 2022 Feb; 17(1):28. PubMed ID: 35148801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of IgA Vasculitis with Nephritis.
    Delbet JD; Parmentier C; Herbez Rea C; Mouche A; Ulinski T
    Paediatr Drugs; 2021 Sep; 23(5):425-435. PubMed ID: 34396492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of IgA nephropathy and IgA vasculitis nephritis in Chinese children.
    Zhong X; Ding J
    Pediatr Nephrol; 2023 Jun; 38(6):1707-1715. PubMed ID: 36348077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study on clinicopathological features and prognosis of IgA vasculitis nephritis and IgA nephropathy in children.
    Lv Y; Fu R; Peng XJ; Wang Y; Yin TT; Deng YQ
    BMC Pediatr; 2023 Aug; 23(1):423. PubMed ID: 37620917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is adiponectin in children with immunoglobulin A vasculitis a suitable biomarker of nephritis in the course of the disease?
    Dyga K; Machura E; Świętochowska E; Ziora K; Szczepańska M
    Endokrynol Pol; 2020; 71(6):512-517. PubMed ID: 32944925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic comparisons of IgA nephropathy and IgA vasculitis nephropathy in children: a ten-year single-center experience.
    Su Q; Liang Y; Wang N; Dou Z; Rong Z; Zhao X; Yu B; Wang Y; Wang X
    Turk J Med Sci; 2021 Oct; 51(5):2683-2689. PubMed ID: 34392671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early clinical course of biopsy-proven IgA vasculitis nephritis.
    Butzer S; Hennies I; Gimpel C; Gellermann J; Schalk G; König S; Büscher AK; Lemke A; Pohl M
    BMC Pediatr; 2022 Oct; 22(1):570. PubMed ID: 36195856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bibliometric analysis of IgA vasculitis nephritis in children from 2000 to 2022.
    Luo F; Li Y; Zhang Y; Song Y; Diao J
    Front Public Health; 2022; 10():1020231. PubMed ID: 36276396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal histopathological manifestations of IgA vasculitis nephritis in children and adults.
    Xu JJ; Cai J; Hu B
    Int Immunopharmacol; 2023 Mar; 116():109760. PubMed ID: 36764272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of urine biomarkers in children with IgA vasculitis nephritis.
    Williams CEC; Toner A; Wright RD; Oni L
    Pediatr Nephrol; 2021 Oct; 36(10):3033-3044. PubMed ID: 33993342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.